Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial

Documenti analoghi

• Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
  di: Linong Ji, et al.
  Pubblicazione: (2024)
• Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6
  di: Jingmin Zhou, et al.
  Pubblicazione: (2025)
• Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial
  di: Amrit Pathak, et al.
  Pubblicazione: (2025)
• Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
  di: Noga C. Minsky, et al.
  Pubblicazione: (2025)
• Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
  di: Melissa‐Rosina Pasqua, et al.
  Pubblicazione: (2025)